A Phase IV Vaccine Study under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE PLUS)
Latest Information Update: 18 Apr 2024
At a glance
- Drugs Ad26.COV2 S (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms ENFORCE
- 08 Mar 2024 Status changed from recruiting to discontinued.
- 22 Jul 2021 New trial record